JENTADUETO XR Drug Patent Profile

Which patents cover Jentadueto Xr, and what generic alternatives are available?

Jentadueto Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and ninety-two patent family members in forty-one countries.

The generic ingredient in JENTADUETO XR is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jentadueto Xr

A generic version of JENTADUETO XR was approved as linagliptin; metformin hydrochloride by SUNSHINE on August 30^th, 2021.

Summary for JENTADUETO XR

International Patents:	292
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	6
Clinical Trials:	1
Drug Prices:	Drug price information for JENTADUETO XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JENTADUETO XR
What excipients (inactive ingredients) are in JENTADUETO XR?	JENTADUETO XR excipients list
DailyMed Link:	JENTADUETO XR at DailyMed

See drug prices for JENTADUETO XR

Recent Clinical Trials for JENTADUETO XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boehringer Ingelheim	Phase 1

See all JENTADUETO XR clinical trials

Pharmacology for JENTADUETO XR

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Paragraph IV (Patent) Challenges for JENTADUETO XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JENTADUETO XR	Extended-release Tablets	linagliptin; metformin hydrochloride	2.5 mg/1000 mg 5 mg/1000 mg	208026	1	2018-03-28

US Patents and Regulatory Information for JENTADUETO XR

JENTADUETO XR is protected by nine US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes					Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No					Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No					Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes					Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No					Y

Expired US Patents for JENTADUETO XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016

EU/EMA Drug Approvals for JENTADUETO XR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Jentadueto	linagliptin, metformin hydrochloride	EMEA/H/C/002279Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.	Authorised	no	no	no	2012-07-19

International Patents for JENTADUETO XR

When does loss-of-exclusivity occur for JENTADUETO XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

Chile

China

Eurasian Patent Organization

European Patent Office

Hong Kong

India

Japan

Mexico

Philippines

Singapore

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JENTADUETO XR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	071175
Australia	2009232043
Brazil	PI0911273
Canada	2720450
Chile	2009000809
China	101983073
China	103083672

Supplementary Protection Certificates for JENTADUETO XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1532149	C300504	Netherlands		PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN ZOUT; REGISTRATION NO/DATE: EU/1/11/707/001-011 20110824
1532149	1190035-4	Sweden		PERIOD OF VALIDITY (FROM - UNTIL): 20230819 - 20260829
1532149	PA2011013	Lithuania		PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011 08 24 EU/1/11/707/002, 2011 08 24 EU/1/11/707/003, 2011 08 24 EU/1/11/707/004, 2011 08 24 EU/1/11/707/005, 2011 08 24 EU/1/11/707/006, 2011 08 24 EU/1/11/707/007, 2011 08 24 EU/1/11/707/008, 2011 08 24 EU/1/11/707/00 2011082
1532149	C20110018 00046	Estonia		PRODUCT NAME: TRAJENTA-LINAGLIPTIN; REG NO/DATE: FINAL 24.08.2011
1532149	91889	Luxembourg		91889, EXPIRES: 20260824
1532149	CA 2011 00030	Denmark
1532149	PA2011013,C1532149	Lithuania		PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011-08-24 EU/1/11/707/002, 2011-08-24 EU/1/11/707/003, 2011-08-24 EU/1/11/707/004, 2011-08-24 EU/1/11/707/005, 2011-08-24 EU/1/11/707/006, 2011-08-24 EU/1/11/707/007, 2011-08-24 EU/1/11/707/008, 2011-08-24 EU/1/11/707/00 2011082

Last updated: May 28, 2026

Jentadueto XR market dynamics and financial trajectory: revenues, share shifts, and exclusivity-driven risk

Jentadueto XR (metformin hydrochloride extended release + linagliptin) sits in the US oral type 2 diabetes market alongside GLP-1 and SGLT2 combinations, with growth constrained by class-level substitution and long-term generic erosion risk. Financial trajectory since launch reflects (1) durability of DPP-4 inhibitor demand in oral regimens, (2) uptake of once-daily fixed-dose combinations, and (3) competitive pressure from incretin and SGLT2 combinations that increasingly displace older oral dual therapy. Near-term sales are most sensitive to US formulary position, payer step therapy, and the timing of generic entry for metformin and linagliptin components.

What is Jentadueto XR, who sells it, and how is it positioned in US type 2 diabetes?

Jentadueto XR is a fixed-dose combination indicated for adults with type 2 diabetes mellitus to improve glycemic control, using:

• Metformin HCl extended release (ER)
• Linagliptin

Commercial positioning

• Oral, once-daily preference: ER metformin plus DPP-4 inhibitor provides convenience and regimen simplification versus separate pills.
• Compared with GLP-1 and SGLT2 strategies: Jentadueto XR competes most directly in “oral-first” and “oral continuation” formulary tiers rather than where payers aggressively steer to injectables or cardiorenal-indicated SGLT2/GLP-1 agents.
• DPP-4 class context: linagliptin has higher value retention than some peers because of renal-friendly profile, but class growth is capped by substitution toward GLP-1 and SGLT2.

Key buyer decision points

• Formulary tier placement and prior authorization requirements
• Step edits (failure on metformin first, then add-on)
• Quantity limits for ER formulations
• Competing fixed-dose combinations (metformin + other DPP-4 inhibitors; GLP-1 oral agents where applicable)

How have Jentadueto XR sales evolved since launch, and what market forces drive the trajectory?

Trajectory pattern typical for oral dual fixed-dose diabetes products

• Launch years: growth supported by prescriber migration to fixed-dose convenience and payer acceptance of DPP-4 add-on after metformin.
• Maturation years: growth slows as prescribers shift toward GLP-1/SGLT2, and as generic penetration in metformin-containing regimens increases payer bargaining power.
• Late-period dynamics: sales become increasingly dependent on differentiation through labeling breadth, dosing simplicity, and pharmacy benefit design.

Market forces pushing down demand

• Incretin substitution: GLP-1 receptor agonists and dual agonists (and SGLT2 inhibitors) gained share as evidence expanded beyond glycemic control into weight and cardiorenal outcomes.
• Generic pricing pressure: while combination products often retain brand premium longer, component and therapeutic-class substitution compress net price over time.
• Payer pathway intensification: step therapy and preferred formulary placement often steer away from older oral dual regimens once alternative classes are covered.

Market forces supporting partial resilience

• Oral adherence advantage: for patients not willing or eligible for injectable therapy, oral dual therapy remains a durable segment.
• DPP-4 tolerability profile: broad use in patients where hypoglycemia risk avoidance matters.
• Fixed-dose convenience: reduces pill burden versus separate agents, improving persistence in chronic regimens.

What exclusivity and patent cliffs most affect Jentadueto XR revenue risk?

Jentadueto XR is a combination of metformin ER and linagliptin. The revenue risk is concentrated in two areas:

1. Product-level patent estate covering the fixed-dose combination, dosing regimen, and/or formulation/manufacturing.
2. Regulatory exclusivity dynamics affecting the ability of generic or “authorized” competitors to launch.

Practical cliff drivers

• Orange Book listed patents: combination and formulation patents are the main constraint on generic entry.
• Paragraph IV pathways: if generic applicants file Abbreviated New Drug Applications and assert non-infringement or invalidity against listed patents, settlements can set a launch date or delay date.
• Exclusivity interaction: even if patents expire, data exclusivity or other regulatory protections can delay approvals depending on the basis of approval.

Because the question is explicitly about market dynamics and financial trajectory, the relevant point for decision-making is that brand sales tend to decline sharply in the window around:

• patent expiration,
• settlement-enforced “carve-out” launch dates,
• or the first effective generic stocking in the pharmacy channel.

How does Jentadueto XR compare financially and commercially with other oral diabetes fixed-dose combinations?

Direct competitive set (US oral dual/triple therapy)

• Metformin ER fixed-dose combinations with other incretin or DPP-4 alternatives.
• Other DPP-4-based add-on oral combinations.
• Metformin + SGLT2 fixed doses (where covered and preferred).
• Metformin + GLP-1 oral options where present in local formularies.

Share and pricing dynamics

• DPP-4 combos face increasing displacement from GLP-1 and SGLT2 because payers increasingly tie coverage to outcomes, and because patients shift with evolving clinical guidance.
• In oral-only formularies or Medicare Part D plans with narrower incretin access, DPP-4 combos can hold price better longer, but remain exposed to generic erosion in the metformin and DPP-4 building blocks.

Net effect on financial trajectory

• Jentadueto XR’s growth rate is typically more volatile than GLP-1/SGLT2 leaders and more sensitive to formulary repricing and generic substitution.
• Margin pressure rises as rebates and contracting intensify in late life-cycle periods.

What is the Orange Book status of Jentadueto XR and how does it shape generic entry risk?

Orange Book status determines the timing and likelihood of generics and biosimilar-type risk. For a brand combination like Jentadueto XR, generic entry risk is shaped by:

• expiration dates of listed patents,
• remaining patent term at the time of Abbreviated New Drug Application approvals,
• and whether Paragraph IV challenges have been filed and settled.

Decision-useful takeaway

• When combination-specific formulation or method patents remain active, generic launch is delayed and sales remain supported by brand protection.
• When those patents clear, the most common pattern is price compression via multiple ANDA launches followed by aggressive contracting.

Are there Paragraph IV filings or patent challenges that could accelerate revenue decline?

Paragraph IV events drive discrete revenue inflection points:

• filing triggers potential 30-month stay of approval,
• settlement can either delay generic launch or allow earlier “at-risk” entry at a defined date,
• and court outcomes can invalidate or uphold key patents.

Commercial implication

• The nearer the expected generic entry date, the more contracting tends to intensify, raising rebate burden and reducing net sales per unit.
• If a court or settlement pushes out entry, net sales can maintain for longer but face renewed pressure when entry eventually occurs.

What does the competitive landscape look like across dosing convenience, formulary access, and payer contracting?

How formulary access changes usage

• “Preferred” status for certain oral duals depends on PBM preference and rebate structures.
• Where prior authorization exists, prescribers often switch to preferred alternatives or agents with easier criteria.
• ER formulations must compete on both total daily dose simplicity and pharmacy fill rates.

How competitors win

• Fixed-dose convenience with once-daily dosing.
• Lower cost-sharing via preferred tier placement.
• Label breadth that matches payer risk programs and clinical pathways.

How Jentadueto XR retains share

• Patients stable on oral therapy.
• Prescriber familiarity in oral add-on settings.
• DPP-4 class tolerability and the renal-friendly positioning for linagliptin.

What financial KPIs matter most for tracking Jentadueto XR performance?

For a brand diabetes combination nearing late lifecycle risk, these KPIs provide the clearest signal:

• US TRx trend (prescription volume): indicates retention vs substitution.
• Net sales and net price realization: indicates rebate and contracting pressure.
• Script-to-sales conversion: reveals channel stocking vs true demand.
• Share of prescriptions among oral duals: measures relative displacement within the category.
• Gross-to-net ratio: rising ratios indicate increased rebate burden due to competitive pressure or generic threats.
• Pipeline of line extensions: delays or re-lauches can affect net performance.

What scenarios could drive downside or upside to Jentadueto XR revenue?

Downside scenarios

• Generic entry that launches earlier than expected or occurs without meaningful settlement delay.
• Formulary downgrades, tighter step edits, or increased prior authorization after PBM renegotiations.
• Continued share loss as incretin and SGLT2 regimens gain coverage expansion.

Upside scenarios

• Settlement outcomes that push generic entry beyond the presumed patent cliff.
• Improved payer outcomes-based contracting that keeps DPP-4 combinations preferred in subsets of patients.
• Higher persistence due to stable patient populations and ER dosing convenience.

Key Takeaways

• Jentadueto XR’s market dynamics are shaped by oral dual therapy demand facing sustained displacement from GLP-1 and SGLT2 strategies.
• Financial trajectory tends to move from launch-supported growth to mature lifecycle stability, then to net price compression as generic and formulary pressure intensify.
• The largest revenue inflection risks center on Orange Book patent expiry for the combination and formulation, and on whether Paragraph IV challenges lead to earlier generic launch.
• Track TRx, net price realization, gross-to-net ratios, and oral dual category share to detect the transition from brand durability to generic-driven erosion.

FAQs

Which payer segments still favor Jentadueto XR?

Commercial managed care and Medicare Part D plans that maintain an oral-first pathway and do not aggressively steer to GLP-1/SGLT2 for glycemic control-only indications.

What is the biggest risk to Jentadueto XR net price?

Generic competition and PBM re-contracting that increases rebate intensity and tier displacement.

Does Jentadueto XR face substitution from other DPP-4 combinations?

Yes, through formulary preference for other fixed-dose DPP-4 or metformin ER combinations, especially when patients can be switched with limited clinical disruption.

How does dosing convenience affect persistence?

Once-daily ER fixed-dose convenience typically improves adherence and persistence relative to multiple-pill regimens, supporting revenue in mid-life-cycle periods.

Is biosimilar risk relevant for Jentadueto XR?

No. The product is a small-molecule combination therapy; the relevant generic risk is via ANDA and paragraph-IV-type patent challenges, not biosimilar pathways.

---

References

No sources were provided in the prompt.